据报道，错配修复缺陷（d-MMR）肿瘤对免疫检查点抑制剂表现出敏感性。我们的目的是评估膀胱浸润性尿路上皮癌中 d-MMR 和 PD-1/PD-L1 表达的相关性。组织微阵列 (TMA) 组织对 PD-1/PD-L1 和 MMR 蛋白进行染色。这些标记物的表达率已与组织病理学参数进行了比较。 d-MMR 肿瘤更具浅表肌肉侵袭性 (p = 0.012)。当检查 d-MMR 和 PD-1/PD-L1 表达比率时，肿瘤和免疫细胞中 d-MMR 和 PD-L1 表达比率之间存在显着相关性，均 > 5% (p = 0.02和 p = 0.004，分别）。在没有 MMR 丢失的患者中，表达率较高。 MSH6 缺失的患者中 PD-1 和 PD-L1 表达为 1 或无。将 PD1/PDL1 表达与组织病理学参数进行比较时，发现肿瘤分级和肌肉浸润深度之间存在显着关系。在浅表肌肉浸润性肿瘤中未观察到 PD-L1 表达。这项研究显示了 d-MMR 和 PD-1/PD-L1 在浸润性尿路上皮癌中的状态及其与预后标志物的相关性。 PD-1/PD-L1 表达可能导致膀胱癌的进展和不良预后。然而，还需要进一步研究来研究其临床效用。

It has been reported that mismatch repair deficient (d-MMR) tumors show sensitivity to immune checkpoint inhibitors. We aimed to evaluate the correlation of d-MMR and PD-1/PD-L1 expression in invasive urothelial carcinoma of the bladder. Tissue microarray (TMA) tissues were stained PD-1/PD-L1 and MMR proteins. The expression ratio of these markers has been compared with histopathologic parameters. d-MMR tumors were more superficial muscle invasive (p = 0.012). When the d-MMR, and PD-1/PD-L1 expression ratios were examined, a significant correlation was obtained between the d-MMR and PD-L1 expression ratio of > 5% in both the tumor and immune cells (p = 0.02 and p = 0.004, respectively). The expression ratio was higher in the patients without MMR loss. PD-1 and PD-L1expression in those with MSH6 loss was one or none. When PD1/PDL1 expression was compared with histopathological parameters, a significant relationship was observed between tumor grade and depth of muscle invasion. PD-L1 expression was not observed in the superficial muscle invasive tumors. This study was shown the status of d-MMR and PD-1/PD-L1 in invasive urothelial cancers and their correlation with prognostic markers. PD-1/PD-L1 expression may contribute to the progression and poor prognosis of bladder cancer. However, further studies are required to research the clinical utility.